Kim, Nayoung <br/><br/>
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.  [electronic resource] 

 -  Oncotarget  Mar 2016 
 - 13797-809 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.7318  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis<br/>Biomarkers, Tumor--genetics<br/>Carcinogenesis<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Proliferation<br/>Drug Resistance, Neoplasm--genetics<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--pharmacology<br/>Genomics--methods<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mice<br/>Mice, Nude<br/>Mutation<br/>Nerve Tissue Proteins--genetics<br/>Protein Kinase Inhibitors--pharmacology<br/>RNA, Small Interfering--genetics<br/>Signal Transduction<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays